These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 12471856

  • 1. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Oct; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 4. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Apr; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 6. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC, Boone D, Gendics C, Todd G.
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [Abstract] [Full Text] [Related]

  • 7. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 8. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Jun; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 Jun; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 10. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Jun 01; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Jun 01; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 13. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A, Rogowski W.
    BMC Health Serv Res; 2009 Jul 10; 9():115. PubMed ID: 19591680
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun 10; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 15. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Jun 10; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun 10; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 17. The costs of diabetic foot: the economic case for the limb salvage team.
    Driver VR, Fabbi M, Lavery LA, Gibbons G.
    J Am Podiatr Med Assoc; 2010 Jun 10; 100(5):335-41. PubMed ID: 20847346
    [Abstract] [Full Text] [Related]

  • 18. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.
    Health Quality Ontario.
    Ont Health Technol Assess Ser; 2017 Jun 10; 17(5):1-142. PubMed ID: 28572866
    [Abstract] [Full Text] [Related]

  • 19. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb 10; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 10; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.